Injectable Paromomycin for Visceral Leishmaniasis in India
Top Cited Papers
Open Access
- 21 June 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (25) , 2571-2581
- https://doi.org/10.1056/nejmoa066536
Abstract
Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in South Asia, Africa, and Brazil. Safe, effective, and affordable new therapies are needed. We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present standard of care in Bihar, India.Keywords
This publication has 23 references indexed in Scilit:
- Leishmaniasis: current situation and new perspectivesComparative Immunology, Microbiology and Infectious Diseases, 2004
- Recent understanding in the treatment of visceral leishmaniasis.Journal of Postgraduate Medicine, 2003
- Advances in the treatment of leishmaniasisCurrent Opinion in Infectious Diseases, 2002
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Failure of Pentavalent Antimony in Visceral Leishmaniasis in India: Report from the Center of the Indian EpidemicClinical Infectious Diseases, 2000
- Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical studyTransactions of the Royal Society of Tropical Medicine and Hygiene, 2000
- Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovaniThe Journal of Infectious Diseases, 1999
- Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first line drug? An observational study of 80 casesPathogens and Global Health, 1998
- Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India Commentary: Some good news for treatment of visceral leishmaniasis in BiharBMJ, 1998
- Response to Interferon‐γ plus Pentavalent Antimony in Indian Visceral LeishmaniasisThe Journal of Infectious Diseases, 1997